Moderna (MRNA) PT Lowered to $238 at Brookline Capital Markets
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann lowered the price target on Moderna (NASDAQ: MRNA) to $238.00 (from $310.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
